Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

ATNM Actinium Pharmaceuticals Inc

9,73

-0,12 (-1,22%)

17 Mai 2024 - Fechado

Atrasado em 15 minutos

Form EFFECT - Notice of Effectiveness

Actinium Pharmaceuticals (AMEX:ATNM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024

Click aqui para mais gráficos Actinium Pharmaceuticals.

Actinium Pharmaceuticals (AMEX:ATNM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024

Click aqui para mais gráficos Actinium Pharmaceuticals.

Notícias Actinium Pharmaceuticals Inc

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Quarta, 15 de Maio de 2024 (4 dias atrás) • PR Newswire (US)

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas
Terça, 14 de Maio de 2024 (4 dias atrás) • PR Newswire (US)

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Segunda, 13 de Maio de 2024 (6 dias atrás) • PR Newswire (US)

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
Terça, 7 de Maio de 2024 (2 semanas atrás) • PR Newswire (US)

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Quinta, 18 de Abril de 2024 (1 mês atrás) • PR Newswire (US)

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual
Segunda, 1 de Abril de 2024 (2 meses atrás) • PR Newswire (US)

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Terça, 26 de Março de 2024 (2 meses atrás) • PR Newswire (US)

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Segunda, 11 de Março de 2024 (2 meses atrás) • PR Newswire (US)

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT
Segunda, 26 de Fevereiro de 2024 (3 meses atrás) • PR Newswire (US)

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB
Sexta, 23 de Fevereiro de 2024 (3 meses atrás) • PR Newswire (US)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Sexta, 9 de Fevereiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Terça, 6 de Fevereiro de 2024 (3 meses atrás) • Edgar (US Regulatory)

Mais Notícias de Actinium Pharmaceuticals Inc

CryptoDash Token

Goldman Sachs Bank Usa P...

Agria Group Holding Ad

Bank of Montreal Autocal...

Invisio Communications Ab

Alpha Partners Technolog...

PETRQ245 Ex:21,62

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições